Moleculin Biotech, Inc. is preclinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology.

Press Releases

Moleculin to Present at the 30th Annual ROTH Conference Tuesday, March 13, 2018

HOUSTON, TX -- (Marketwired) -- 03/06/18 -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that Walter Klemp, chief executive officer and Jon Foster, chief financial officer, will present at the 30th Annual ROTH Conference on Tuesday, March 13, 2018 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) in Yellow - Salon 6. The conference is being held at the Ritz-Carlton Hotel in Dana Point, California from March 11-14, 2018.

A webcast of the presentation will be available at the Investor Relations page of the Company's website at www.moleculin.com. The webcast and presentation will be archived on the Company's website for 90 days following the event.

The Company will also host investor meetings throughout the day on Tuesday, March 13, 2018. Attendance at the conference is by invitation only for clients of ROTH Capital Markets. Interested investors should contact your ROTH Capital Markets sales representative or Lytham Partners at (602) 889-9700 or mbrx@lythampartners.com to secure a meeting time.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of oncology drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Our clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML. We are also engaged in preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors.